END 7-OH Act

Legislative bill overview

HR 8000, the "END 7-OH Act," was introduced in March 2026 and referred to both the Energy and Commerce Committee and the Judiciary Committee. Based on the title acronym, this bill likely addresses regulation or restriction of 7-hydroxymitragynine (7-OH), a primary alkaloid compound found in kratom. The dual committee referral suggests the bill contains both regulatory/commercial and legal/enforcement components.

Why is this important

Kratom is a botanical product used by millions of Americans, generating a significant market and consumer base. Congressional action on kratom's legal status would have substantial implications for vendors, consumers, and the dietary supplement industry. The bill's outcome could affect product availability, pricing, and the legal landscape for kratom across all 50 states.

Potential points of contention

• Consumer access vs. safety concerns: Kratom advocates argue for consumer choice and natural product access, while some regulators and health officials cite concerns about safety, addiction potential, and unregulated quality standards
• Federal vs. state authority: The bill may conflict with existing state-level kratom regulations, creating jurisdictional disputes and compliance challenges for businesses operating across multiple states
• Scientific evidence interpretation: Disagreement exists over kratom's safety profile and medical benefits, with stakeholders citing different research conclusions regarding efficacy and adverse effects